An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
Launched by XVIVO PERFUSION · Oct 29, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The XVIVO Registry is a clinical trial designed to gather important information about a new method for assessing donor lungs before a transplant. This method is called Normothermic Ex Vivo Lung Perfusion (EVLP), which means the lungs are treated with a special system to keep them functioning outside the body before they are transplanted. The study aims to understand how well this system works over time and to monitor any serious side effects related to its use. Additionally, data from previous studies will be included to provide insights into the long-term safety and quality of life for patients who have received these transplants.
Anyone aged 65 to 74 who is receiving lungs treated with the EVLP method can participate in this trial, as it includes all patients who meet this criterion. Participants can expect to have their clinical information collected and monitored throughout the process to help improve future lung transplant procedures. This study is currently recruiting participants, and it aims to ensure better outcomes for future lung transplant patients.
Gender
ALL
Eligibility criteria
- • This is an "All Comers Registry" hence will include all patients receiving EVLP lungs.
About Xvivo Perfusion
XVIVO Perfusion is a pioneering medical technology company dedicated to advancing organ preservation and transplantation. With a focus on innovative perfusion solutions, the company develops cutting-edge systems that optimize organ viability and enhance transplant outcomes. XVIVO Perfusion's commitment to research and development drives its efforts to improve the overall success rates of organ transplants, ultimately benefiting patients in need of life-saving procedures. By collaborating with healthcare providers and academic institutions, XVIVO Perfusion aims to transform the landscape of transplantation through its state-of-the-art technologies and clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Cleveland, Ohio, United States
Patients applied
Trial Officials
Jaya Tiwari, BS, CCRP
Study Director
XVIVO Perfusion Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials